GLI1 activates pro-fibrotic pathways in myelofibrosis fibrocytes.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
20 05 2022
Historique:
received: 17 12 2021
accepted: 09 05 2022
revised: 05 05 2022
entrez: 20 5 2022
pubmed: 21 5 2022
medline: 25 5 2022
Statut: epublish

Résumé

Bone marrow (BM) fibrosis was thought to be induced exclusively by mesenchymal stromal cells (MSCs). However, we and others found that neoplastic fibrocytes induce BM fibrosis in myelofibrosis (MF). Because glioma-associated oncogene-1 (GLI1), an effector of the Hedgehog pathway, plays a role in the induction of BM fibrosis, we wondered whether GLI1 affects fibrocyte-induced BM fibrosis in MF. Multiplexed fluorescence immunohistochemistry analysis of MF patients' BM detected high levels of GLI1 in MF fibrocytes compared to MSCs or normal fibrocytes. Immunostaining, RNA in situ hybridization, gene expression analysis, and western immunoblotting detected high levels of GLI1 and GLI1-induced matrix metalloproteases (MMP) 2 and 9 in MF patients BM-derived cultured fibrocytes. Similarly, MF patients' BM-derived GLI1

Identifiants

pubmed: 35595725
doi: 10.1038/s41419-022-04932-4
pii: 10.1038/s41419-022-04932-4
pmc: PMC9122946
doi:

Substances chimiques

GLI1 protein, human 0
Hedgehog Proteins 0
STAT3 Transcription Factor 0
Zinc Finger Protein GLI1 0
Matrix Metalloproteinase 2 EC 3.4.24.24
Matrix Metalloproteinase 9 EC 3.4.24.35

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

481

Informations de copyright

© 2022. The Author(s).

Références

J Clin Oncol. 2005 Nov 20;23(33):8520-30
pubmed: 16293880
Nat Rev Cancer. 2002 May;2(5):361-72
pubmed: 12044012
J Exp Med. 2016 Aug 22;213(9):1723-40
pubmed: 27481130
Br J Haematol. 2018 Apr;181(1):133-137
pubmed: 28220930
ACS Chem Biol. 2016 Feb 19;11(2):308-18
pubmed: 26730496
Oncotarget. 2021 Mar 02;12(5):401-411
pubmed: 33747356
Mol Cancer Res. 2008 Dec;6(12):1928-36
pubmed: 19074837
Leukemia. 2021 Feb;35(2):454-467
pubmed: 32472085
Leuk Lymphoma. 2015 Jul;56(7):2092-7
pubmed: 25641433
Cancer Cell. 2008 Sep 9;14(3):238-49
pubmed: 18772113
Blood. 2014 May 29;123(22):e123-33
pubmed: 24740812
PLoS One. 2009 Oct 16;4(10):e7475
pubmed: 19834619
Am J Pathol. 2012 Dec;181(6):2126-37
pubmed: 23031257
Cell Stem Cell. 2009 Jun 5;4(6):548-58
pubmed: 19497283
Blood. 2019 May 23;133(21):2320-2324
pubmed: 30745304
Blood. 2013 Apr 25;121(17):3345-63
pubmed: 23462118
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8455-60
pubmed: 17494766
J Biol Chem. 2007 Aug 3;282(31):22910-20
pubmed: 17556364
Wien Klin Wochenschr. 2020 Aug;132(15-16):464-466
pubmed: 31712882
Mol Med. 1994 Nov;1(1):71-81
pubmed: 8790603
Blood. 2018 May 10;131(19):2111-2119
pubmed: 29572380
J Immunol Methods. 2009 Dec 31;351(1-2):62-70
pubmed: 19818792
Leukemia. 2017 Dec;31(12):2709-2716
pubmed: 28386106
Ann Hematol. 2006 Apr;85(4):226-32
pubmed: 16421727
Nat Rev Immunol. 2011 Jun;11(6):427-35
pubmed: 21597472
Cell Stem Cell. 2009 Jun 5;4(6):559-67
pubmed: 19497284
Cell Stem Cell. 2017 Jun 1;20(6):785-800.e8
pubmed: 28457748
Int J Clin Exp Pathol. 2017 Aug 01;10(8):8605-8609
pubmed: 31966716
J Biol Chem. 2002 Nov 15;277(46):44061-7
pubmed: 12226090
Blood Adv. 2020 Jul 14;4(13):3063-3071
pubmed: 32634234
Biochem J. 1998 Sep 1;334 ( Pt 2):297-314
pubmed: 9716487
J Clin Invest. 2008 Oct;118(10):3331-42
pubmed: 18802480
Oncogene. 2018 May;37(19):2502-2514
pubmed: 29449694
Leukemia. 2008 Jan;22(1):226-8
pubmed: 17928882
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Cancer Res. 2011 Jun 1;71(11):3831-40
pubmed: 21512135
FEBS J. 2011 Jan;278(1):16-27
pubmed: 21087457
Blood. 1981 Apr;57(4):781-7
pubmed: 7470627
Cell Stem Cell. 2015 Jan 8;16(1):51-66
pubmed: 25465115
Curr Treat Options Oncol. 2019 Jan 24;20(1):5
pubmed: 30675650
Am J Pathol. 2012 Apr;180(4):1441-53
pubmed: 22342522
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14016-21
pubmed: 19666525
Cell Stem Cell. 2017 Aug 3;21(2):166-177
pubmed: 28777943
Am J Physiol Lung Cell Mol Physiol. 2001 May;280(5):L999-1008
pubmed: 11290525
Trends Cell Biol. 2007 Sep;17(9):438-47
pubmed: 17845852
Genes Dev. 2008 Sep 15;22(18):2454-72
pubmed: 18794343
Exp Biol Med (Maywood). 2008 Aug;233(8):989-96
pubmed: 18480422
Cancer Discov. 2015 Mar;5(3):316-31
pubmed: 25572172
J Mol Cell Biol. 2010 Apr;2(2):84-95
pubmed: 20083481
J Invest Dermatol. 2019 Feb;139(2):300-307
pubmed: 30291846
Haematologica. 2016 Jun;101(6):660-71
pubmed: 27252511
PLoS One. 2019 Sep 30;14(9):e0222912
pubmed: 31569199

Auteurs

Taghi Manshouri (T)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Ivo Veletic (I)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Ping Li (P)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

C Cameron Yin (CC)

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Sean M Post (SM)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Srdan Verstovsek (S)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Zeev Estrov (Z)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. zestrov@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH